Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmatrix (PULM) Current Deferred Revenue (2019 - 2024)

Pulmatrix (PULM) has disclosed Current Deferred Revenue for 6 consecutive years, with $270000.0 as the latest value for Q2 2024.

  • Quarterly Current Deferred Revenue fell 75.65% to $270000.0 in Q2 2024 from the year-ago period, while the trailing twelve-month figure was $270000.0 through Jun 2024, down 75.65% year-over-year, with the annual reading at $618000.0 for FY2023, 53.85% down from the prior year.
  • Current Deferred Revenue hit $270000.0 in Q2 2024 for Pulmatrix, down from $363000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $12.0 million in Q1 2020 to a low of $270000.0 in Q2 2024.
  • Historically, Current Deferred Revenue has averaged $2.7 million across 5 years, with a median of $1.4 million in 2022.
  • Biggest five-year swings in Current Deferred Revenue: plummeted 89.82% in 2021 and later skyrocketed 42.6% in 2022.
  • Year by year, Current Deferred Revenue stood at $4.2 million in 2020, then tumbled by 77.46% to $939000.0 in 2021, then skyrocketed by 42.6% to $1.3 million in 2022, then crashed by 53.85% to $618000.0 in 2023, then crashed by 56.31% to $270000.0 in 2024.
  • Business Quant data shows Current Deferred Revenue for PULM at $270000.0 in Q2 2024, $363000.0 in Q1 2024, and $618000.0 in Q4 2023.